Bessemer Group Inc. Purchases New Stake in Collegium Pharmaceutical Inc (COLL)

Share on StockTwits

Bessemer Group Inc. bought a new position in shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 32,300 shares of the specialty pharmaceutical company’s stock, valued at approximately $555,000. Bessemer Group Inc. owned about 0.10% of Collegium Pharmaceutical at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. State Board of Administration of Florida Retirement System lifted its stake in Collegium Pharmaceutical by 4.8% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 14,359 shares of the specialty pharmaceutical company’s stock worth $247,000 after purchasing an additional 655 shares during the last quarter. Meeder Asset Management Inc. lifted its stake in Collegium Pharmaceutical by 644.8% during the fourth quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock worth $62,000 after purchasing an additional 3,179 shares during the last quarter. Teachers Advisors LLC lifted its stake in Collegium Pharmaceutical by 6.2% during the third quarter. Teachers Advisors LLC now owns 77,036 shares of the specialty pharmaceutical company’s stock worth $1,136,000 after purchasing an additional 4,484 shares during the last quarter. Monarch Partners Asset Management LLC lifted its stake in Collegium Pharmaceutical by 19.2% during the fourth quarter. Monarch Partners Asset Management LLC now owns 33,770 shares of the specialty pharmaceutical company’s stock worth $580,000 after purchasing an additional 5,430 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund bought a new stake in Collegium Pharmaceutical during the fourth quarter worth $103,000.

In other news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $15.56, for a total value of $389,000.00. Following the completion of the transaction, the director now directly owns 286,000 shares in the company, valued at approximately $4,450,160. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.87% of the stock is currently owned by corporate insiders.

COLL has been the subject of several recent analyst reports. BidaskClub upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 27th. Cantor Fitzgerald set a $35.00 target price on Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Friday, November 30th. ValuEngine cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Monday, January 7th. Zacks Investment Research upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research note on Wednesday, January 9th. Finally, Needham & Company LLC restated a “buy” rating and set a $33.00 target price (down from $35.00) on shares of Collegium Pharmaceutical in a research note on Wednesday, January 16th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Collegium Pharmaceutical presently has an average rating of “Buy” and a consensus price target of $29.80.

Shares of COLL opened at $16.98 on Monday. Collegium Pharmaceutical Inc has a 52 week low of $13.10 and a 52 week high of $28.91. The firm has a market capitalization of $574.18 million, a PE ratio of -14.27 and a beta of 0.35. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.26 and a quick ratio of 1.21.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.65. Collegium Pharmaceutical had a negative return on equity of 41.12% and a negative net margin of 13.95%. The company had revenue of $73.40 million during the quarter, compared to analysts’ expectations of $72.71 million. During the same period in the prior year, the company earned ($0.54) EPS. Collegium Pharmaceutical’s revenue was up 579.6% compared to the same quarter last year. As a group, analysts expect that Collegium Pharmaceutical Inc will post -0.14 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/4229710/bessemer-group-inc-purchases-new-stake-in-collegium-pharmaceutical-inc-coll.html.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Article: Purposes and Functions of the Federal Reserve

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Reviewing Sutro Biopharma  and Brainstorm Cell Therapeutics
Reviewing Sutro Biopharma and Brainstorm Cell Therapeutics
Select Energy Services Inc  Expected to Post Earnings of $0.13 Per Share
Select Energy Services Inc Expected to Post Earnings of $0.13 Per Share
Analog Devices  Sets New 52-Week High at $115.93
Analog Devices Sets New 52-Week High at $115.93
Total System Services  Hits New 12-Month High at $100.98
Total System Services Hits New 12-Month High at $100.98
Sequans Communications SA  Receives Average Recommendation of “Buy” from Analysts
Sequans Communications SA Receives Average Recommendation of “Buy” from Analysts
$300.10 Million in Sales Expected for Aegion Corp  This Quarter
$300.10 Million in Sales Expected for Aegion Corp This Quarter


© 2006-2019 Ticker Report